Skip to main content
Caplight Logo









Agnos Therapeutics

Agnos Therapeutics

Private
Baltimore, MarylandHealthcare & Life Scienceshttps://agnostx.com/

Last Round

VC Round

Jan 29, 2026

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Agnos Therapeutics is a biotechnology company developing mutation-agnostic, iPSC-derived retinal cell therapies to restore vision for patients with inherited blindness.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cell therapyinherited retinal diseasesIRDinduced pluripotent stem celliPSCregenerative medicinemutation-agnostic therapyoff-the-shelf therapybiotechretinal cell therapydrug discoveryblindness treatmentallogeneic cell therapyclinical-stage biopharmaorphan drug

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Agnos Therapeutics Comparables

Compare Agnos Therapeutics with similar companies based on industry and business-model similarity.

Agnos Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Opsis Therapeutics
86%
jCyte, Inc.
80%
SparingVision
80%

Agnos Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJan 29, 2026
Pre SeedJun 10, 2025
GrantMay 14, 2024

Agnos Therapeutics Investors

Notable investors and investment history

Agnos Therapeutics investors
InvestorRounds
Johns Hopkins Technology VenturesPre Seed
Maryland Stem Cell Research FundGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 29, 2026

    Completed a VC Round fundraise.

Agnos Therapeutics Filings

Explore SEC and related filing metadata, where available.

Agnos Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Agnos Therapeutics's valuation, stock price, and market status.

Is Agnos Therapeutics a public or private company?

Agnos Therapeutics is a private company.

What is the current stock price of Agnos Therapeutics?

Agnos Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Agnos Therapeutics worth (valuation)?

Valuation information for Agnos Therapeutics is not publicly available.

Can I buy Agnos Therapeutics stock?

Agnos Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Agnos Therapeutics's last funding round?

Agnos Therapeutics's most recent funding round was VC Round on January 29, 2026.

Who are the main investors in Agnos Therapeutics?

Key investors in Agnos Therapeutics include Johns Hopkins Technology Ventures, Maryland Stem Cell Research Fund.

Will Agnos Therapeutics IPO soon?

No public IPO plans have been announced for Agnos Therapeutics.

How can I track Agnos Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Agnos Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBaltimore, Maryland
Employee Range3
Year Founded2025
Last FundingJan 29, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?